C-myc基因和P16基因在肝细胞癌中的表达及其临床意义

郭晓林; 姜雅秋; 迟宝荣

C-myc基因和P16基因在肝细胞癌中的表达及其临床意义

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2030
- HTML全文浏览量: 12
- PDF下载量: 927
- 被引次数: 0
出版历程
- 出版日期: 2007-06-20

The clinical significance of C-myc and P16 gene's expression in hepatocellular carcinoma

摘要

摘要: 目的探讨C-myc基因和P16基因表达在肝细胞癌（HCC）中的临床意义。方法采用免疫组化检测技术检测不同肝癌组织、癌旁组织及正常肝组织中的C-myc基因和P16基因表达产物。结果C-myc基因表达产物在肝癌组织中的表达明显高于癌旁组织和正常肝组织（P<0.05）。P16基因表达产物则在正常肝组织中和癌旁组织中表达明显高于肝癌组织（P<0.05）。C-myc基因的表达与HCC的发病年龄、性别、肿瘤大小、UICC分期无关（P>0.05）,而与HCC的转移有关（P<0.05）;P16基因的表达与HCC的发病年龄、性别、肿瘤大小无关（P>0.05）,而与HCC的转移和UICC分期有关（P<0.05）。结论C-myc基因表达增强与P16基因表达障碍能促进HCC的发生发展,并可用来判断预后。
- 肝细胞癌 /
- C-myc基因 /
- P16基因
Abstract: Objective To approach the clinical significance of C-myc and P16 gene's expression in hepatocellular carcinoma (HCC) .Methods C-myc and P16 gene's expression in HCC tissue and cancer adjacent liver tissue and normal liver tissue were detected by immunohistochemistry.Results The expression of C-myc in HCC tissue was higher than that in cancer adjacent liver tissue and normal liver tissue (P<0.05) .The expression of C-myc had no association with the patients'age, sex, the size of tumor and UICC stage (P>0.05) .It had some association with the patients'age, sex, the size of tumor (P>0.05) .The expression of P16 had some association with the UICC stage and the metastasis of HCC (P<0.05) .Conclusion The enhancement of expression of C-myc and the disorder of expression of P16 could promote the occurrence and development of HCC and could be used as prognostic factors.
- hepatocellular carcinoma /
- C-myc gene /
- P16 gene

HTML全文

参考文献(9)

[1]Jonas JC, Laybutt DR, Steil GM, et al.High glucose stimulates ear-ly response gene c-myc expression in rat pancreatic beta cells[J].JBiol Chem, 2001, 276 (38) ∶35375-81.

[2]Fields WR, Desiderio JG, PutnamKP, et al.Quantification of chan-ges in c-myc mRNA levels in normal human bronchial epithelial (NHBE) and lung adenocarcioma (A549) cells following chemicaltreatment[J].Toxicol Sci, 2001, 63 (1) ∶107-14.

[3]Hermeking H.The MYC oncogene as a cancer drug target[J].CurrCancer Drug Targets, 2003, 3 (3) ∶163-75.

[4]Wang Y, Wu MC, Sham JS, et al.Prognostic significance of c-myc and A1B1 amplification in hepatocellular carcinoma.A broadsurvey using high-throughput tissue microarry[J].Cancer, 2002, 95 (11) 2346-52.

[5]周梅芳, 沈明明, 杨健.P16基因的失活与肝癌生物学行为的关系[J].江苏医药, 2006, 32 (5) ∶488.

[6]单铁英, 董永杰, 刘晓霞.P16基因产物在人类肝细胞癌中的表达及临床意义[J].长治医学院学报, 2006, 20 (2) ∶86-8.

[7]陈龙邦, 林京力, 唐永明.原发性肝癌患者血清p16和DAPK基因启动子甲基化的研究[J].肿瘤防治研究, 2006, 33 (3) ∶175-7.

[8]Wu Y, Renard CA, Apiou F, et al.Recurrent allelic deletions atmouse chromosomes 4 and 14 in Myc-induced liver tumors[J].On-cogene, 2002, 21 (10) ∶1518-26.

[9]Simile MM.Downregulation of c-myc and Cyclin D1genes by anti-sense oligodeoxy nucleotides inhibits the expression of E2F1 and invitro growth of HepG2 and Morris 5123 liver cancer cells[J].Carci-nogenesis, 2003, 25 (3) ∶333-4.

施引文献

资源附件(0)

访问统计